Clinical bottom line
Relapsed or refractory acquired aplastic anemia (AA) remains a challenging clinical scenario with limited standardized treatment options. Recent advances highlight the potential of thrombopoietin receptor agonists (TPO-RAs) such as eltrombopag and avatrombopag, as well as immunosuppressive therapies including alemtuzumab, as promising salvage therapies. However, the evidence is largely derived from retrospective studies and small cohorts, underscoring the need for further prospective validation. Emerging molecular insights may soon inform novel targeted approaches, but current management primarily involves individualized immunosuppression and supportive care.
What the evidence shows
Treatment of relapsed or refractory acquired AA traditionally relies on immunosuppressive therapy (IST) with agents such as antithymocyte globulin (ATG) and cyclosporine, but a subset of patients fail to respond or relapse (Füreder et al., 2011). Alemtuzumab, a monoclonal antibody targeting CD52, has demonstrated activity as monotherapy in relapsed and refractory severe AA, with response rates around 30–40% in small series (Scheinberg et al., 2012). This approach offers an alternative immunosuppressive strategy, particularly for patients ineligible for hematopoietic stem cell transplantation (HSCT).
More recently, TPO-RAs have gained attention for their ability to stimulate residual hematopoiesis. Eltrombopag, initially approved for thrombocytopenia, has shown efficacy in refractory AA, inducing hematologic responses in approximately 40–50% of patients (Füreder et al., 2011; Kernel Networks Inc., 2019). A retrospective single-center study comparing eltrombopag and avatrombopag suggested comparable efficacy and safety profiles, with avatrombopag offering an oral option with potentially fewer hepatotoxic effects (Zhang et al., 2023). These agents may be used alone or in combination with IST, although optimal sequencing remains undefined.
Pediatric AA treatment paradigms differ somewhat, with HSCT favored for younger patients with matched donors, but refractory cases still pose therapeutic dilemmas (Locasciulli et al., 1999). The heterogeneity of response and disease biology in children versus adults necessitates age-specific considerations.
On the horizon, integrative proteomic and transcriptomic analyses have identified novel molecular targets implicated in AA pathogenesis, offering hope for future targeted therapies (Li et al., 2024). However, these findings remain preliminary and require clinical translation.
Caveats and uncertainty
The evidence base for relapsed/refractory AA therapies is limited by small sample sizes, retrospective designs, and heterogeneous patient populations. Many studies lack randomized controls, and long-term safety data for newer agents like TPO-RAs in this setting are sparse. The comparative effectiveness of eltrombopag versus avatrombopag remains to be confirmed in prospective trials.
Alemtuzumab’s immunosuppressive effects raise concerns about infectious complications and secondary malignancies, necessitating careful patient selection and monitoring (Scheinberg et al., 2012). Additionally, the definition of refractory and relapsed AA varies across studies, complicating interpretation and generalizability (National Cancer Institute et al., 2020).
Pediatric data are older and less robust, with treatment algorithms evolving alongside advances in transplantation and supportive care (Locasciulli et al., 1999). Emerging molecular targets identified through omics approaches are hypothesis-generating and not yet clinically actionable (Li et al., 2024).
How this may change practice
Clinicians managing relapsed or refractory acquired AA should consider TPO-RAs such as eltrombopag or avatrombopag as viable salvage options, particularly for patients unsuitable for HSCT or further IST. Alemtuzumab remains a potential immunosuppressive alternative, though its use requires balancing efficacy with infection risk.
Incorporation of molecular profiling may soon refine patient stratification and enable personalized therapy, but this remains investigational. Multidisciplinary care involving hematologists, transplant specialists, and infectious disease experts is essential to optimize outcomes.
Ongoing clinical trials and real-world registries will be critical to establish standardized treatment algorithms, define long-term safety, and clarify the role of novel agents. Until then, treatment decisions should be individualized, guided by patient age, comorbidities, prior therapies, and donor availability.